Andrew Conway Morris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3933234/publications.pdf

Version: 2024-02-01

86 papers

4,276 citations

147801 31 h-index 62 g-index

97 all docs 97
docs citations

97 times ranked 5569 citing authors

#	Article	IF	CITATIONS
1	ARDS subphenotypes: searching for Rorschach among the roentgenograms?. Thorax, 2022, 77, 2-4.	5.6	2
2	Novel treatments and trials in COVID-19., 2022, , 109-120.		1
3	Invasive Pulmonary Aspergillosis in Hospital and Ventilator-Associated Pneumonias. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 234-242.	2.1	8
4	Perspectives of patients, family members, health professionals and the public on the impact of COVID-19 on mental health. Journal of Mental Health, 2022, 31, 524-533.	1.9	2
5	New Movement in Sepsis Immunotherapeutics—A Role for Prokineticin 2?*. Critical Care Medicine, 2022, 50, 714-716.	0.9	O
6	Undiagnosed attention-deficit/hyperactivity disorder may be a risk factor for requiring anaesthesia. British Journal of Anaesthesia, 2022, 128, e221-e222.	3.4	1
7	Chimeric Antigen Receptor T Cells, the Shock of the New*. Critical Care Medicine, 2022, 50, 157-160.	0.9	O
8	Molecular diagnostics in severe pneumonia: a new dawn or false promise? Intensive Care Medicine, 2022, , $1.$	8.2	6
9	Clinical and organizational factors associated with mortality during the peak of first COVID-19 wave: the global UNITE-COVID study. Intensive Care Medicine, 2022, 48, 690-705.	8.2	38
10	Proteomic, biomechanical and functional analyses define neutrophil heterogeneity in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2021, 80, 209-218.	0.9	43
11	Response. Chest, 2021, 159, 1681-1682.	0.8	O
12	Paired Nasopharyngeal and Deep Lung Testing for Severe Acute Respiratory Syndrome Coronavirus-2 Reveals a Viral Gradient in Critically III Patients. Chest, 2021, 159, 1387-1390.	0.8	13
13	Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19. Blood Advances, 2021, 5, 635-639.	5.2	52
14	Core Outcome Measures for Trials in People With Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery. Critical Care Medicine, 2021, 49, 503-516.	0.9	41
15	Ventilator-associated pneumonia in critically ill patients with COVID-19. Critical Care, 2021, 25, 25.	5.8	217
16	The excess insulin requirement in severe COVIDâ€19 compared to nonâ€COVIDâ€19 viral pneumonitis is related to the severity of respiratory failure and preâ€existing diabetes. Endocrinology, Diabetes and Metabolism, 2021, 4, e00228.	2.4	6
17	Phosphoinositide 3-Kinase $\hat{\Gamma}$ Inhibition Improves Neutrophil Bacterial Killing in Critically Ill Patients at High Risk of Infection. Journal of Immunology, 2021, 207, 1776-1784.	0.8	3
18	Neutrophil kinetics and function after major trauma: A systematic review. World Journal of Critical Care Medicine, 2021, 10, 260-277.	1.8	6

#	Article	IF	CITATIONS
19	Post-mortem dissection of COVID-19: a pathogenic role for macrophages?. Intensive Care Medicine, 2021, 47, 1322-1325.	8.2	9
20	Rapid Assay for Sick Children with Acute Lung infection Study (RASCALS): diagnostic cohort study protocol. BMJ Open, 2021, 11, e056197.	1.9	5
21	The Effects of Escalation of Respiratory Support and Prolonged Invasive Ventilation on Outcomes of Cardiac Surgical Patients: A Retrospective Cohort Study. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 1226-1234.	1.3	7
22	Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation. Lancet Respiratory Medicine, the, 2020, 8, 182-191.	10.7	65
23	Contrasting effects of linezolid on healthy and dysfunctional human neutrophils: reducing C5a-induced injury. Scientific Reports, 2020, 10, 16377.	3.3	5
24	International Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019. Critical Care Medicine, 2020, 48, 1612-1621.	0.9	12
25	Core Outcomes Set for Trials in People With Coronavirus Disease 2019. Critical Care Medicine, 2020, 48, 1622-1635.	0.9	47
26	More research is required to understand factors influencing antibiotic prescribing in complex conditions like suspected ventilator-associated pneumonia. Annals of Translational Medicine, 2020, 8, 840-840.	1.7	4
27	Pulmonary infections complicating ARDS. Intensive Care Medicine, 2020, 46, 2168-2183.	8.2	69
28	Personal protective equipment and intensive care unit healthcare worker safety in the COVID-19 era (PPE-SAFE): An international survey. Journal of Critical Care, 2020, 59, 70-75.	2.2	234
29	Pulmonary Aspergillosis in Patients with Suspected Ventilator-associated Pneumonia in UK ICUs. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1125-1132.	5.6	34
30	Antimicrobial-associated harm in critical care: a narrative review. Intensive Care Medicine, 2020, 46, 225-235.	8.2	86
31	C5a impairs phagosomal maturation in the neutrophil through phosphoproteomic remodeling. JCI Insight, 2020, 5, .	5.0	26
32	Evaluating the use of a 22-pathogen TaqMan array card for rapid diagnosis of respiratory pathogens in intensive care. Journal of Medical Microbiology, 2020, 69, 971-978.	1.8	17
33	Perceived differences between intensivists and infectious diseases consultants facing antimicrobial resistance: a global cross-sectional survey. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1235-1240.	2.9	15
34	A global priority list of the TOp TEn resistant Microorganisms (TOTEM) study at intensive care: a prioritization exercise based on multi-criteria decision analysis. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 319-323.	2.9	97
35	Nebulization of antimicrobial agents in mechanically ventilated adults in 2017: an international cross-sectional survey. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 785-794.	2.9	25
36	Immune Activation in Sepsis. Critical Care Clinics, 2018, 34, 29-42.	2.6	59

#	Article	IF	Citations
37	Early PREdiction of sepsis using leukocyte surface biomarkers: the ExPRES-sepsis cohort study. Intensive Care Medicine, 2018, 44, 1836-1848.	8.2	59
38	C5a anaphylatoxin and its role in critical illnessâ€induced organ dysfunction. European Journal of Clinical Investigation, 2018, 48, e13028.	3.4	28
39	Ventilator-Associated Pneumoniaâ€"Quantum Uncertainty in the ICU?*. Critical Care Medicine, 2018, 46, 1007-1008.	0.9	O
40	Randomised controlled trial of GM-CSF in critically ill patients with impaired neutrophil phagocytosis. Thorax, 2018, 73, 918-925.	5.6	41
41	Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study. Intensive Care Medicine, 2018, 44, 627-635.	8.2	97
42	16S pan-bacterial PCR can accurately identify patients with ventilator-associated pneumonia. Thorax, 2017, 72, 1046-1048.	5.6	31
43	Novel role for endogenous mitochondrial formylated peptide-driven formyl peptide receptor 1 signalling in acute respiratory distress syndrome. Thorax, 2017, 72, 928-936.	5.6	64
44	Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial. Trials, 2016, 17, 318.	1.6	17
45	Early PREdiction of Severe Sepsis (ExPRES-Sepsis) study: protocol for an observational derivation study to discover potential leucocyte cell surface biomarkers. BMJ Open, 2016, 6, e011335.	1.9	5
46	Predictive value of cell-surface markers in infections in critically ill patients: protocol for an observational study (ImmuNe FailurE in Critical Therapy (INFECT) Study). BMJ Open, 2016, 6, e011326.	1.9	8
47	Interaction of mitochondrial formylated peptides with formyl peptide receptor 1 in the pathogenesis of acute lung injury. Lancet, The, 2016, 387, S38.	13.7	1
48	Reply to Zelyas and Robinson. Clinical Infectious Diseases, 2016, 63, 142.2-143.	5.8	0
49	Low-pathogenicity <i>Mycoplasma </i> spp. alter human monocyte and macrophage function and are highly prevalent among patients with ventilator-acquired pneumonia. Thorax, 2016, 71, 594-600.	5.6	22
50	Role of regulatory T cells in neutrophil function. Lancet, The, 2016, 387, S30.	13.7	3
51	Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. Clinical Infectious Diseases, 2016, 62, 817-823.	5.8	322
52	Exchange protein directly activated by cyclic AMP (EPAC) activation reverses neutrophil dysfunction induced by \hat{l}^22 -agonists, corticosteroids, and critical illness. Journal of Allergy and Clinical Immunology, 2016, 137, 535-544.	2.9	28
53	Use of enoximone in management of anaphylaxis complicated by labetalol use. BMJ Case Reports, 2015, 2015, bcr2015212432.	0.5	2
54	Triage during pandemic influenza: seeking absolution in numbers?. British Journal of Anaesthesia, 2015, 114, 865-867.	3.4	2

#	Article	IF	Citations
55	Development of two real-time multiplex PCR assays for the detection and quantification of eight key bacterial pathogens in lower respiratory tract infections. Clinical Microbiology and Infection, 2015, 21, 788.e1-788.e13.	6.0	90
56	Diagnostic accuracy of pulmonary host inflammatory mediators in the exclusion of ventilator-acquired pneumonia. Thorax, 2015, 70, 41-47.	5.6	59
57	Serial characterisation of monocyte and neutrophil function after lung resection. BMJ Open Respiratory Research, 2014, 1, e000045.	3.0	5
58	Differential response to bacteria, and TOLLIP expression, in the human respiratory tract. BMJ Open Respiratory Research, 2014, 1, e000046.	3.0	8
59	Reply: The Alveolar Macrophage and Acute Respiratory Distress Syndrome: A Silent Actor?. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 500-501.	5.6	0
60	Leukoreduced blood transfusion does not increase circulating soluble markers of inflammation: a randomized controlled trial. Transfusion, 2014, 54, 2404-2411.	1.6	10
61	A national survey of the diagnosis and management of suspected ventilator-associated pneumonia. BMJ Open Respiratory Research, 2014, 1, e000066.	3.0	32
62	Functional characterisation of human pulmonary monocyte-like cells in lipopolysaccharide-mediated acute lung inflammation. Journal of Inflammation, 2014, 11, 9.	3.4	8
63	V. Ventilator associated pneumonia: can we ensure that a quality indicator does not become a game of chance?. British Journal of Anaesthesia, 2013, 111, 333-337.	3.4	11
64	Clinical outcomes and macrolide resistance in Mycoplasma pneumoniae infection in Scotland, UK. Journal of Medical Microbiology, 2013, 62, 1876-1882.	1.8	32
65	A Randomized Controlled Trial of Peripheral Blood Mononuclear Cell Depletion in Experimental Human Lung Inflammation. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 449-455.	5.6	21
66	Combined dysfunctions of immune cells predict nosocomial infection in critically ill patients. British Journal of Anaesthesia, 2013, 111, 778-787.	3.4	65
67	Comment on "Changes and Regulation of the C5a Receptor on Neutrophils during Septic Shock in Humans― Journal of Immunology, 2013, 191, 4893-4893.	0.8	О
68	Antibiotic Prophylaxis for Ventilator-Associated Pneumonia. Chest, 2013, 144, 1734-1735.	0.8	0
69	Ventilator-Associated Pneumonia Is Characterized by Excessive Release of Neutrophil Proteases in the Lung. Chest, 2012, 142, 1425-1432.	0.8	588
70	Monocytes Control Second-Phase Neutrophil Emigration in Established Lipopolysaccharide-induced Murine Lung Injury. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 514-524.	5.6	104
71	A novel subpopulation of monocyte-like cells in the human lung after lipopolysaccharide inhalation. European Respiratory Journal, 2012, 40, 206-214.	6.7	30
72	Pulmonary and systemic effects of mononuclear leukapheresis. Vox Sanguinis, 2012, 103, 275-283.	1.5	3

#	Article	IF	Citations
73	Reducing ventilator-associated pneumonia in intensive care: Impact of implementing a care bundle*. Critical Care Medicine, 2011, 39, 2218-2224.	0.9	220
74	C5a-mediated neutrophil dysfunction is RhoA-dependent and predicts infection in critically ill patients. Blood, 2011, 117, 5178-5188.	1.4	97
75	Thromboprophylaxis in Intensive Care: A Nationwide, Multidisciplinary Quality Improvement Project. Journal of the Intensive Care Society, 2010, 11, 174-178.	2.2	1
76	Diagnostic importance of pulmonary interleukin-1Â and interleukin-8 in ventilator-associated pneumonia. Thorax, 2010, 65, 201-207.	5.6	95
77	Pain in medical inpatients: an under-recognised problem?. Journal of the Royal College of Physicians of Edinburgh, The, 2009, 39, 292-295.	0.6	15
78	C5a Mediates Peripheral Blood Neutrophil Dysfunction in Critically III Patients. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 19-28.	5.6	103
79	Evaluation of the effect of diagnostic methodology on the reported incidence of ventilator-associated pneumonia. Thorax, 2009, 64, 516-522.	5 . 6	78
80	Recent human-to-poultry host jump, adaptation, and pandemic spread of <i>Staphylococcus aureus</i> Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19545-19550.	7.1	363
81	Trappin-2 Promotes Early Clearance of Pseudomonas aeruginosa through CD14-Dependent Macrophage Activation and Neutrophil Recruitment. American Journal of Pathology, 2009, 174, 1338-1346.	3.8	37
82	Chest pain presenting to the Emergency Departmentâ€"to stratify risk with GRACE or TIMI?. Resuscitation, 2007, 74, 90-93.	3.0	96
83	TIMI risk score accurately risk stratifies patients with undifferentiated chest pain presenting to an emergency department. Heart, 2006, 92, 1333-1334.	2.9	48
84	Management of pneumonia in intensive care. Journal of Emergency and Critical Care Medicine, 0, 2, 101-101.	0.7	22
85	Development and implementation of a customised rapid syndromic diagnostic test for severe pneumonia. Wellcome Open Research, 0, 6, 256.	1.8	2
86	Development and implementation of a customised rapid syndromic diagnostic test for severe pneumonia. Wellcome Open Research, 0, 6, 256.	1.8	2